Erica C Kaye1, Jonathan Jerkins2, Courtney A Gushue3, Samantha DeMarsh4, April Sykes5, Zhaohua Lu5, Jennifer M Snaman6, Lindsay Blazin5, Liza-Marie Johnson5, Deena R Levine5, R Ray Morrison5, Justin N Baker5. 1. St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Electronic address: erica.kaye@stjude.org. 2. Le Bonheur Children's Hospital, Memphis, Tennessee, USA; University of Tennessee Health Science Center, Memphis, Tennessee, USA. 3. Nationwide Children's Hospital, Columbus, Ohio, USA. 4. Ohio University Heritage College of Osteopathic Medicine, Cleveland, Ohio, USA. 5. St. Jude Children's Research Hospital, Memphis, Tennessee, USA. 6. Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Boston Children's Hospital, Boston, Massachusetts, USA.
Abstract
CONTEXT: Early integration of palliative care (PC) in the management of children with high-risk cancer is widely endorsed by patients, families, clinicians, and national organizations. However, optimal timing for PC consultation is not standardized, and variables that influence timing of PC integration for children with cancer remain unknown. OBJECTIVES: To investigate associations between demographic, disease, treatment, and end-of-life attributes and timing of PC consultation for children with high-risk cancer enrolled on a PC service. METHODS: A comprehensive standardized tool was used to abstract data from the medical records of 321 patients treated at a large academic pediatric cancer center, who died between 2011 and 2015. RESULTS: Gender, race, ethnicity, enrollment on a Phase I protocol, number of high-acuity hospitalizations, and receipt of cardiopulmonary resuscitation were not associated with timing of PC involvement. Patients with hematologic malignancy, those who received cancer-directed therapy during the last month of life, and those with advance directives documented one week or less before death had higher odds of late PC referral (malignancy: odds ratio [OR] 3.24, P = 0.001; therapy: OR 4.65, P < 0.001; directive: OR 4.81, P < 0.0001). Patients who received hospice services had lower odds of late PC referral <30 days before death (OR 0.31, P < 0.001). CONCLUSION: Hematologic malignancy, cancer-directed therapy at the end of life, and delayed documentation of advance directives are associated with late PC involvement in children who died of cancer. Identification of these variables affords opportunities to study targeted interventions to enhance access to earlier PC resources and services for children with high-risk cancer and their families.
CONTEXT: Early integration of palliative care (PC) in the management of children with high-risk cancer is widely endorsed by patients, families, clinicians, and national organizations. However, optimal timing for PC consultation is not standardized, and variables that influence timing of PC integration for children with cancer remain unknown. OBJECTIVES: To investigate associations between demographic, disease, treatment, and end-of-life attributes and timing of PC consultation for children with high-risk cancer enrolled on a PC service. METHODS: A comprehensive standardized tool was used to abstract data from the medical records of 321 patients treated at a large academic pediatric cancer center, who died between 2011 and 2015. RESULTS: Gender, race, ethnicity, enrollment on a Phase I protocol, number of high-acuity hospitalizations, and receipt of cardiopulmonary resuscitation were not associated with timing of PC involvement. Patients with hematologic malignancy, those who received cancer-directed therapy during the last month of life, and those with advance directives documented one week or less before death had higher odds of late PC referral (malignancy: odds ratio [OR] 3.24, P = 0.001; therapy: OR 4.65, P < 0.001; directive: OR 4.81, P < 0.0001). Patients who received hospice services had lower odds of late PC referral <30 days before death (OR 0.31, P < 0.001). CONCLUSION:Hematologic malignancy, cancer-directed therapy at the end of life, and delayed documentation of advance directives are associated with late PC involvement in children who died of cancer. Identification of these variables affords opportunities to study targeted interventions to enhance access to earlier PC resources and services for children with high-risk cancer and their families.
Authors: Justin N Baker; Shesh Rai; Wei Liu; Kumar Srivastava; Javier R Kane; Christine A Zawistowski; Elizabeth A Burghen; Jami S Gattuso; Nancy West; Jennifer Althoff; Adam Funk; Pamela S Hinds Journal: J Palliat Med Date: 2009-01 Impact factor: 2.947
Authors: T David Elkin; Scott A Jensen; Lacy McNeil; Mary Elizabeth Gilbert; Jeanette Pullen; Linda McComb Journal: J Pediatr Oncol Nurs Date: 2007 Sep-Oct Impact factor: 1.636
Authors: Donna L Johnston; Kim Nagel; Debra L Friedman; Jane L Meza; Craig A Hurwitz; Sarah Friebert Journal: J Clin Oncol Date: 2008-10-01 Impact factor: 44.544
Authors: Erica C Kaye; Jared Rubenstein; Deena Levine; Justin N Baker; Devon Dabbs; Sarah E Friebert Journal: CA Cancer J Clin Date: 2015-05-07 Impact factor: 508.702
Authors: Nicholas P DeGroote; Kristen E Allen; Erin E Falk; Cristina Velozzi-Averhoff; Karen Wasilewski-Masker; Khaliah Johnson; Katharine E Brock Journal: Support Care Cancer Date: 2021-08-19 Impact factor: 3.603
Authors: Maya N McKee; Brett K Palama; Matt Hall; James L LaBelle; Nicole L Bohr; K Sarah Hoehn Journal: Pediatr Crit Care Med Date: 2022-02-22 Impact factor: 3.971
Authors: Erica C Kaye; Samantha DeMarsh; Courtney A Gushue; Jonathan Jerkins; April Sykes; Zhaohua Lu; Jennifer M Snaman; Lindsay J Blazin; Liza-Marie Johnson; Deena R Levine; R Ray Morrison; Justin N Baker Journal: Oncologist Date: 2018-05-04
Authors: Emily J Labudde; Nicholas P DeGroote; Susie Smith; Jonathan Ebelhar; Kristen E Allen; Sharon M Castellino; Karen Wasilewski-Masker; Katharine E Brock Journal: Cancer Med Date: 2021-03-22 Impact factor: 4.452
Authors: Katharine E Brock; Kristen E Allen; Erin Falk; Cristina Velozzi-Averhoff; Nicholas P DeGroote; Jeffrey Klick; Karen Wasilewski-Masker Journal: Support Care Cancer Date: 2020-08-11 Impact factor: 3.603
Authors: A McCauley Massie; Jonathan Ebelhar; Kristen E Allen; Nicholas P DeGroote; Karen Wasilewski-Masker; Katharine E Brock Journal: Neurooncol Pract Date: 2021-03-12